“…With regard to clinical science, the potential applications of nanotechnology are huge, and has already generated a range of promising examples, such as conceptually new medical diagnostics, imaging agents and therapeutics (using new drug-delivery platforms) for detecting and treating diseases [18,[26][27][28][29] in the early stages . The advantages of early detection are not limited to cancer, and many other disorders such as Alzheimer disease are presumed to cause disruptive changes well before clinical manifestations become obvious, but profoundly nanotechnology provides an unprecedented opportunity to build better detection strategies and tools, and places the rapidly evolving field of [19, 'nanodiagnostics' at the front line in the war on diseases 30,31] . Although, pharmacogenomics focuses on the identification of genetic variants thatinfluence drug effects, typically through alterations in pharmacokinetics and new emerging analytical approaches have facilitated the evolution of a discovery model from hitherto promising drug candidates towards agnostic genome-wide analyses of patient populations with specific drug-response phenotypes highlighting "toxicity or desired pharmacological [32,33] effects .…”